Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinopharm Raises $716 Million in Secondary Offering

publication date: Nov 24, 2014
Sinopharm Group, China's largest drug distribution company, raised $716 million through a secondary issue to a "handful" of institutional investors, who purchased 199 million new shares. The issue increases Sinopharm's outstanding shares by 7.74%. The company said the new capital will help Sinopharm expand its network (it did not specify whether the growth would come from internal growth or through M&A) and to replenish liquidity after its already completed growth initiatives. More details....

Stock Symbol: (HK: 1099)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital